Quanterix, a Lexington company specializing in technology designed for the early detection of diseases, said Thursday that it has closed an $18.5 million Series C financing. Quanterix added that it has also entered a strategic agreement with bioMerieux, a French company that plans to use Quanterix’s Simoa technology to develop specialized tests that focus on infectious diseases. As part of the financing, bioMerieux has taken an initial $15 million equity stake in Quanterix.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help